
Join to view full profile
505 S 45th StOmaha, NE 68198
Phone+1 402-559-5600
Fax+1 402-595-1296
Dr. Marr is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Nebraska Medical Center College of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 2003 - 2006
University of Nebraska College of MedicineClass of 2003
Certifications & Licensure
NE State Medical License 2006 - 2028
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- Sunitinib in Patients With Various Solid Tumors With/Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Gordan Srkalovic, Michael Rothe, Elizabeth Garrett-Mayer, Kathryn F Mileham, Bamidele Adesunloye
JCO Precision Oncology. 2026-10-01 - Temsirolimus in Patients With Solid Tumors WithMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Evan Pisick, Michael Rothe, Elizabeth Garrett-Mayer, Gordan Srkalovic, John K Chan
JCO Precision Oncology. 2026-04-01 - 3 citationsOlaparib in Patients With Solid Tumors WithAlterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Tareq Al Baghdadi, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Oxana V Crysler
JCO Precision Oncology. 2025-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: